Leukemia, Acute Myeloid; Aml

Incidence and onset information

Alternative names

Leukemia, Acute Myeloid; Aml Is also known as leukemia, acute myelogenous.

Researches and researchers

Doctors, researchs, and experts related to Leukemia, Acute Myeloid; Aml extracted from public data.

Leukemia, Acute Myeloid; Aml Experts map

Current Researchs and researchers

• GRAZ — Pr Armin ZEBISCH

  Investigator of research project
  
  

  • Institution/s:
    — Universitätsklinik für Innere Medizin, Medizinische Universität Graz
  • Research area/topic::
    

    The role of RKIP in myeloid leukemogenesis



• LINZ — Pr Andreas PETZER

  Principal investigator of clinical trial - Investigator of clinical trial - Investigator of research project
  
  

  • Institution/s:
    — Krankenhaus der Barmherzigen Schwestern Linz
  • Research area/topic::
    

    AMLSG BiO: Registry Study on Patient Characteristics, Biological Disease Profile and Clinical Outcome in Acute Myeloid Leukemia and Related Neoplasms, and Higher Risk Myelodysplastic Syndrome - The Biology and Outcome (BiO)-Project - AT



• WIEN — Pr Philipp STABER

  Clinical expert - Principal investigator of clinical trial - Investigator of research project
  
  

  • Institution/s:
    — Universitätsklinik für Innere Medizin I, Allgemeines Krankenhaus der Stadt Wien
  • Research area/topic::
    

    EXALT: A Prospective Investigator-initiated Translational Study Evaluating Individualized Treatment Regiments Based on Respective Biomarker Analyses for Refractory Leukemia and Lymphoma Patients



• WIEN — Pr Rotraud WIESER

  Investigator of research project
  
  

  • Institution/s:
    — Universitätsklinik für Innere Medizin I, Allgemeines Krankenhaus der Stadt Wien
  • Research area/topic::
    

    Functional interactions between EVI1 and atRA in LSCs (in acute myeloid leukemia)



• LEUVEN — Pr Peter A VANDENBERGHE

  Responsible for diagnostic tests - Investigator of research project
  
  

  • Institution/s:
    — Department of Human Genetics, University Hospitals Leuven - Gasthuisberg
  • Research area/topic::
    

    The role of RAS- and RHO-GTPases, their regulators and mediators in the pathogenesis of myeloid malignancies.



• TORONTO — Pr Raymond M REILLY

  Investigator of research project
  
  

  • Institution/s:
    — University of Toronto
  • Research area/topic::
    

    CD123-Targeted Auger Electron Radioimmunotherapy of Acute Myelogenous Leukemia (AML)



• BERLIN — Pr Christian HAGEMEIER

  Coordinator of research network
  
  

  • Institution/s:
    — Otto-Heubner-Centrum für Kinder- und Jugendmedizin
  • Research area/topic::
    

    NGFN plus: Leukemia Network - functional and translational studies on acute lymphoblastic leukemia in childhood -terminated



• DRESDEN — Dr Christoph RÖLLIG

  Principal investigator of clinical trial - Investigator of research project
  
  

  • Institution/s:
    — Medizinische Klinik und Poliklinik I, Universitätsklinikum Carl Gustav Carus an der TU Dresden
  • Research area/topic::
    

    AML Registry: Clinical AML Registry



• DRESDEN — Dr Martin WERMKE

  Principal investigator of clinical trial - Investigator of research project
  
  

  • Institution/s:
    — Medizinische Klinik und Poliklinik I, Universitätsklinikum Carl Gustav Carus an der TU Dresden
  • Research area/topic::
    

    ALLIVE (ALLogeneic Iron inVEstigators) Observational Trial: Assessment of body, liver and labile plasma iron and their association with outcome and immunological recovery in Myelodysplastic syndromes or Acute Myeloid Leukemia patients undergoing allogeneic stem cell transplantation



• ESSEN — Pr Dirk REINHARDT

  Coordinator of expert centre - Responsible for diagnostic tests - Principal investigator of clinical trial - Investigator of research project
  
  

  • Institution/s:
    — Zentrum für Kinder- und Jugendmedizin, Universitätsklinikum Essen
    — Westdeutsches Tumorzentrum Essen (WTZ)
  • Research area/topic::
    

    AML-BFM Registry 2012: Clinical registry for children and adolescents with acute myeloid leukemia



• HANNOVER — Pr Ursula CREUTZIG

  Principal investigator of clinical trial - Investigator of research project
  
  

  • Institution/s:
    — KPOH Geschäftsführung Hannover
  • Research area/topic::
    

    AML-BFM Registry 2012: Clinical registry for children and adolescents with acute myeloid leukemia



• HANNOVER — Pr Teruko TAMURA-NIEMANN

  Investigator of research project
  
  

  • Institution/s:
    — Zentrum Biochemie, Medizinische Hochschule Hannover
  • Research area/topic::
    

    Signal transduction of c-Kit and c-Kit related tyrosine kinases: mRNA export and hematopoesis



• HANNOVER — Pr Roland SEIFERT

  Investigator of research project - Director of department
  
  

  • Institution/s:
    — Zentrum Pharmakologie und Toxikologie, Medizinische Hochschule Hannover
  • Research area/topic::
    

    The histamine H2-receptor as new target for differentiation therapy in acute myeloic leukemia



• HEIDELBERG — Pr Olaf WITT

  Clinical expert - Principal investigator of clinical trial - Investigator of research project - Director of department
  
  

  • Institution/s:
    — Deutsches Krebsforschungszentrum
    — Deutsches Krebsforschungszentrum
  • Research area/topic::
    

    INFORM-Registry: INdividualized Therapy FOr Relapsed Malignancies in Childhood



• MANNHEIM — Dr Susanne SAUßELE

  Coordinator of expert centre - Clinical expert - Principal investigator of clinical trial - Investigator of research project - Coordinator of research network
  
  

  • Institution/s:
    — III. Medizinische Universitäts-Klinik, Universitätsklinikum Mannheim
    — Universitätsmedizin Mannheim
  • Research area/topic::
    

    Competence Network 'acute and chronic leukemias'



• MANNHEIM — Pr Rüdiger HEHLMANN

  Principal investigator of clinical trial - Investigator of research project - Coordinator of research network - Director of department
  
  

  • Institution/s:
    — III. Medizinische Universitäts-Klinik, Universitätsklinikum Mannheim
    — Universitätsklinikum Mannheim
  • Research area/topic::
    

    EUROPEAN LEUKEMIA NET: Strengthen and develop scientific and technological excellence in research and therapy of leukemia (coordination)



• MARBURG — Pr Andreas NEUBAUER

  Coordinator of expert centre - Clinical expert - Investigator of research project - Director of department
  
  

  • Institution/s:
    — Universitätsklinikum Gießen und Marburg GmbH, Standort Marburg
    — Universitätsklinikum Gießen und Marburg GmbH, Standort Marburg
  • Research area/topic::
    

    Cooperation of Ras induced signaling and the nuclear oncogene Ski in acute myeloid leukemia (AML) and malignant melanoma (TRR 17: Ras-dependent pathways in human cancer)



• ULM — Pr Christian BUSKE

  Investigator of research project
  
  

  • Institution/s:
    — Universitätsklinikum Ulm
  • Research area/topic::
    

    Impact of the fusion gene CALM - AF10 expression in the pathogenesis of t(10;11)(p13q14) positive leukemia (German Cancer Aid)



• ULM — Dr Michaela FEURING-BUSKE

  Investigator of research project
  
  

  • Institution/s:
    — Universitätsklinikum Ulm
  • Research area/topic::
    

    Characterising normal versus leukemic stem cells in patients with acute myeloic leukemia (German Cancer Aid)



• ULM — Pr Konstanze DÖHNER

  Clinical expert - Principal investigator of clinical trial - Investigator of research project
  
  

  • Institution/s:
    — Universitätsklinikum Ulm am Oberen Eselsberg
  • Research area/topic::
    

    Molecular Genetic and Functional Characterization of Candidate Genes Located in the Commonly Deleted Region at Chromosomal Bands 7q22-q31 in Myeloid Leukemias



• ULM — Pr Hartmut DÖHNER

  Coordinator of expert centre - Principal investigator of clinical trial - Investigator of research project
  
  

  • Institution/s:
    — Universitätsklinikum Ulm am Oberen Eselsberg
    — Integratives Tumorzentrum des Universitätsklinikums Ulm
  • Research area/topic::
    

    ERA-NET TRANSCAN: DRAMA - Defeating Recurrence and resistance in AML: Multigenomic Approaches to analyse heterogeneity -partner DE



• — Dr Tomasz SZCZEPANSKI

  Investigator of research project
  
  

  • Institution/s:
    — Instytut Genetyki Czlowieka - Institute of Human Genetics
  • Research area/topic::
    

    Assessment of treatment effectiveness in childhood acute lymphoblastic leukaemia by monitoring minimal residual disease with 8-color flow cytometry



• CÓRDOBA — Dr Rafael SOLANA LARA

  Investigator of research project
  
  

  • Institution/s:
    — IMIBIC - Instituto Maimónides de Investigación Biomédica de Córdoba
  • Research area/topic::
    

    Implications of immunosenescence in the design of antitumor immunotherapy protocols based on NK cells in melanoma and acute myeloid leukemia models



• LAS PALMAS — Dr Cristina BILBAO SIEYRO

  Investigator of research project
  
  

  • Institution/s:
    — Hospital Universitario de Gran Canaria, Doctor Negrín
  • Research area/topic::
    

    Implication of the epigenetic regulators BRD4, EZH2 and ASXL1 in acute myeloid leukemia



• MADRID — Dr Rosa AYALA DÍAZ

  Principal investigator of clinical trial - Investigator of research project
  
  

  • Institution/s:
    — Hospital Universitario 12 de Octubre
    — Instituto de Investigación Hospital 12 de Octubre
  • Research area/topic::
    

    Molecular alterations involved in the mechanisms of refractoriness and relapse of Acute Myeloid Leukemia: Therapeutic Implications



• VALENCIA — Dr Pau MONTESINOS FERNÁNDEZ

  Principal investigator of clinical trial - Investigator of research project - Manager of registry
  
  

  • Institution/s:
    — Hospital Universitario y Politécnico La Fe
  • Research area/topic::
    

    VILMA: Therapeutic Results in Acute Mieloblastic Leukemia in Patients Older Than 60 Years or Not Candidates for Intensive Chemotherapy - ES



• VALENCIA — Dr Miguel Angel SANZ ALONSO

  Coordinator of expert centre - Clinical expert - Principal investigator of clinical trial - Investigator of clinical trial - Investigator of research project - Director of department
  
  

  • Institution/s:
    — Hospital Universitario y Politécnico La Fe
    — IIS La Fe - Instituto de Investigación Sanitaria La Fe
    — Servicio de Hematología, Hospital Universitario y Politécnico La Fe
  • Research area/topic::
    

    Tracking and validation of mutations in the non-coding regions and spliceosome genes in acute myeloblastic leukemia (AML)



• HUDDINGE — Pr Eva HELLSTRÖM-LINDBERG

  Clinical expert - Investigator of research project
  
  

  • Institution/s:
    — Karolinska Universitetssjukhuset - Solna
    — Karolinska Institutet, Karolinska Institutet - Huddinge
  • Research area/topic::
    

    Molecular pathogenesis in myelodysplastic syndromes and acute myeloid leukemia



• STOCKHOLM — Pr Eva HELLSTRÖM-LINDBERG

  Clinical expert - Investigator of research project
  
  

  • Institution/s:
    — Karolinska Universitetssjukhuset - Solna
    — Karolinska Institutet, Karolinska Institutet - Huddinge
  • Research area/topic::
    

    Molecular pathogenesis in myelodysplastic syndromes and acute myeloid leukemia



• STOCKHOLM — Dr Sören LEHMANN

  Investigator of research project
  
  

  • Institution/s:
    — Karolinska Universitetssjukhuset - Huddinge
  • Research area/topic::
    

    Study of chemotherapy resistance and DNA methylation in acute myeloid leukemia samples

Leukemia, Acute Myeloid; Aml Recommended genes panels

Panel Name, Specifity and genes Tested/covered
KRAS Sequence Analysis. By Baylor Miraca Genetics Laboratories (United States). KRAS Specificity 100 % Genes 5 %
KRAS Sequence Analysis (Familial Mutation/Variant Analysis). By Baylor Miraca Genetics Laboratories (United States). KRAS Specificity 100 % Genes 5 %
KRAS Sequence Analysis (Prenatal Diagnosis). By Baylor Miraca Genetics Laboratories (United States). KRAS Specificity 100 % Genes 5 %
PreSeek Non-invasive Prenatal Gene Sequencing Screen. By Baylor Miraca Genetics Laboratories (United States). RIT1, BRAF, SMC1A, SOS1, SOS2, CDKL5, SYNGAP1, TSC1, TSC2, HDAC8, NSD1, CBL, SHOC2, CHD7, COL1A2, SMC3, NIPBL, FGFR2, FGFR3, HRAS , (...) View the complete list with 9 more genes Panel complete gene list RIT1, BRAF, SMC1A, SOS1, SOS2, CDKL5, SYNGAP1, TSC1, TSC2, HDAC8, NSD1, CBL, SHOC2, CHD7, COL1A2, SMC3, NIPBL, FGFR2, FGFR3, HRAS, JAG1, KRAS, MAP2K1, MAP2K2, MECP2, NRAS, PTPN11, RAD21, RAF1 Close Specificity 7 % Genes 10 %
KRAS/RAF1/SOS1 DNA Sequencing Evaluation. By Athena Diagnostics Inc (United States). SOS1, KRAS, RAF1 Specificity 34 % Genes 5 %
KRAS DNA Sequencing Test. By Athena Diagnostics Inc (United States). KRAS Specificity 100 % Genes 5 %
Non-immune Hydrops Panel. By Greenwood Genetic Center Diagnostic Laboratories Greenwood Genetic Center (United States). RIT1, RPL11, RPL35A, RPL5, RPS10, RPS17, RPS19, RPS24, RPS26, SEC23B, SLC17A5, BRAF, SMPD1, SOS1, SOS2, SOX18, UROS, CBL, SHOC2, ALG9 , (...) View the complete list with 66 more genes Panel complete gene list RIT1, RPL11, RPL35A, RPL5, RPS10, RPS17, RPS19, RPS24, RPS26, SEC23B, SLC17A5, BRAF, SMPD1, SOS1, SOS2, SOX18, UROS, CBL, SHOC2, ALG9, CDAN1, KAT6B, ALG1, CHRNA1, CHRND, CHRNG, CANT1, KIAA0586, CLCNKA, CLCNKB, SUMF1, PEX26, FAT4, DHCR7, PIEZO1, WDR35, CCBE1, GNPTAB, FGFR3, FOXC2, G6PD, GALNS, GATA1, GBA, GBE1, GLA, GLB1, GUSB, HADHA, HADHB, HRAS, IDUA, FOXP3, KLF1, KIF23, KRAS, LBR, LIPA, LZTR1, MAP2K1, MAP2K2, MID1, KMT2D, ASAH1, MVK, NEU1, NPC1, NRAS, PEX1, PEX10, PEX12, PEX13, PEX14, PEX16, PEX3, PEX6, PIGA, PKLR, PMM2, CTSA, PTH1R, PTPN11, PEX19, PEX5, RAF1, RASA1 Close Specificity 2 % Genes 5 %
NGS RASopathy Panel. By Greenwood Genetic Center Diagnostic Laboratories Greenwood Genetic Center (United States). RIT1, RRAS, BRAF, SOS1, SOS2, CBL, SHOC2, KAT6B, SPRED1, A2ML1, CABIN1, NSUN2, HRAS, KRAS, LZTR1, MAP2K1, MAP2K2, NF1, NF2, NRAS , (...) View the complete list with 3 more genes Panel complete gene list RIT1, RRAS, BRAF, SOS1, SOS2, CBL, SHOC2, KAT6B, SPRED1, A2ML1, CABIN1, NSUN2, HRAS, KRAS, LZTR1, MAP2K1, MAP2K2, NF1, NF2, NRAS, PTPN11, RAF1, RASA2 Close Specificity 5 % Genes 5 %

Sources and references

You can check the following sources for additional information.

If you liked this article maybe you will also find interesting the following in-depth articles about other rare diseases, like ROBINOW SYNDROME, AUTOSOMAL DOMINANT 2; DRS2 NEU-LAXOVA SYNDROME 2; NLS2 WELL-DIFFERENTIATED LIPOSARCOMA SYMPHALANGISM, PROXIMAL, 1A; SYM1A HYPEROSTOSIS CRANIALIS INTERNA LYMPHOBLASTIC LEUKEMIA, ACUTE, WITH LYMPHOMATOUS FEATURES; LALL